The decision means that HEC Pharma and other drugmakers would potentially be able to launch a generic version of Gilenya 0.5mg imminently, pending further legal action, she said.
“In the event of a generic launch in the United States, we expect fiscal year 2022 sales to be negatively impacted by US$0.3 billion. growth in group revenue and core operating profit, we continue to expect both to be in the mid-single digit range, constant exchange rates,” he added.